Novo Nordisk A/S (NVO) DCF Valuation

Novo Nordisk A/S (NVO) DCF Valuation

DK | Healthcare | Biotechnology | NYSE
Novo Nordisk A/S (NVO) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Novo Nordisk A/S (NVO) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Simplify Novo Nordisk A/S (NVO) valuation with this customizable DCF Calculator! Featuring real Novo Nordisk A/S (NVO) financials and adjustable forecast inputs, you can test scenarios and uncover Novo Nordisk A/S (NVO) fair value in minutes.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020		 AY2
2021		 AY3
2022		 AY4
2023		 AY5
2024		 FY1
2025		 FY2
2026		 FY3
2027		 FY4
2028		 FY5
2029
Revenue 17,696.0 19,627.2 24,667.0 32,376.7 40,481.6 49,881.3 61,463.7 75,735.4 93,320.9 114,989.8
Revenue Growth, % 0 10.91 25.68 31.26 25.03 23.22 23.22 23.22 23.22 23.22
EBITDA 8,163.8 9,036.6 10,651.7 15,798.1 19,150.0 23,090.8 28,452.4 35,058.9 43,199.5 53,230.3
EBITDA, % 46.13 46.04 43.18 48.79 47.31 46.29 46.29 46.29 46.29 46.29
Depreciation 735.5 740.3 920.3 1,312.2 1,191.2 1,861.0 2,293.1 2,825.6 3,481.7 4,290.1
Depreciation, % 4.16 3.77 3.73 4.05 2.94 3.73 3.73 3.73 3.73 3.73
EBIT 7,428.4 8,296.3 9,731.4 14,486.0 17,958.8 21,229.8 26,159.2 32,233.3 39,717.8 48,940.2
EBIT, % 41.98 42.27 39.45 44.74 44.36 42.56 42.56 42.56 42.56 42.56
Total Cash 1,778.3 2,437.4 3,286.2 4,214.0 3,667.3 5,772.7 7,113.1 8,764.7 10,799.9 13,307.6
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 4,486.4 6,523.7 8,016.1 10,491.2 12,185.3
Account Receivables, % 25.35 33.24 32.5 32.4 30.1
Inventories 2,583.9 2,735.1 3,399.6 4,434.4 5,694.3 6,991.5 8,614.9 10,615.3 13,080.1 16,117.3
Inventories, % 14.6 13.94 13.78 13.7 14.07 14.02 14.02 14.02 14.02 14.02
Accounts Payable 796.9 1,236.5 2,172.8 3,569.4 4,021.1 4,047.3 4,987.1 6,145.1 7,572.0 9,330.1
Accounts Payable, % 4.5 6.3 8.81 11.02 9.93 8.11 8.11 8.11 8.11 8.11
Capital Expenditure -3,078.0 -1,029.5 -2,056.5 -5,422.0 -7,152.4 -6,523.6 -8,038.4 -9,904.8 -12,204.7 -15,038.6
Capital Expenditure, % -17.39 -5.25 -8.34 -16.75 -17.67 -13.08 -13.08 -13.08 -13.08 -13.08
Tax Rate, % 20.6 20.6 20.6 20.6 20.6 20.6 20.6 20.6 20.6 20.6
EBITAT 5,891.5 6,706.3 7,823.9 11,581.0 14,259.0 16,979.1 20,921.6 25,779.5 31,765.5 39,141.3
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -2,724.4 4,668.1 5,467.1 5,357.8 5,795.5 7,908.1 10,934.8 13,473.9 16,602.5 20,457.5
WACC, % 4.91 4.92 4.91 4.91 4.91 4.91 4.91 4.91 4.91 4.91
PV UFCF
SUM PV UFCF 58,938.4
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 20,867
Terminal Value 716,064
Present Terminal Value 563,356
Enterprise Value 622,294
Net Debt 12,146
Equity Value 610,148
Diluted Shares Outstanding, MM 4,461
Equity Value Per Share 136.79

What You Will Get

  • Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real NVO financials.
  • Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
  • Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
  • Automatic Calculations: Instantly observe the effects of your inputs on Novo Nordisk’s valuation.
  • Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
  • User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.

Key Features

  • Real-Life NVO Data: Pre-filled with Novo Nordisk’s historical financials and forward-looking projections.
  • Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures.
  • Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
  • Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
  • User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Novo Nordisk A/S (NVO) data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Novo Nordisk A/S (NVO)’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Novo Nordisk A/S (NVO)?

  • Accurate Data: Up-to-date Novo Nordisk financials provide trustworthy valuation outcomes.
  • Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Pre-configured calculations save you from starting from the ground up.
  • Professional-Grade Tool: Tailored for investors, analysts, and consultants in the healthcare sector.
  • User-Friendly: Intuitive design and guided instructions make it accessible for all users.

Who Should Use Novo Nordisk A/S (NVO)?

  • Healthcare Investors: Make informed investment choices with insights from a leading pharmaceutical company.
  • Market Analysts: Access comprehensive data to streamline your research on diabetes and obesity treatments.
  • Healthcare Consultants: Tailor presentations and reports with up-to-date information on Novo Nordisk's product pipeline.
  • Pharmaceutical Enthusiasts: Enhance your knowledge of the biopharmaceutical industry through real-life case studies.
  • Students and Educators: Utilize it as a resource for learning about biotechnology and healthcare economics.

What the Template Contains

  • Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Novo Nordisk A/S (NVO).
  • Real-World Data: Novo Nordisk’s historical and projected financials preloaded for thorough analysis.
  • Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
  • Key Ratios: Built-in analysis covering profitability, efficiency, and leverage metrics.
  • Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results regarding Novo Nordisk A/S (NVO).


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.

No products were found matching.